Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05786040 · ClinicalTrials.gov registry record · Phase 2
Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder
A Phase 2 study of Polymorphic Post-Transplant Lymphoproliferative Disorder and Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder, sponsored by Timothy Voorhees.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 3
- Study locations
NCT05786040 is a Phase 2 study of Polymorphic Post-Transplant Lymphoproliferative Disorder and Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder that is actively recruiting participants, run by Timothy Voorhees. The registered enrollment target is 28 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT05786040, a Phase 2 study of Polymorphic Post-Transplant Lymphoproliferative Disorder and Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder, is actively recruiting participants, sponsored by Timothy Voorhees.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 3
- Study locations
Study Summary
This phase II trial tests how well tafasitamab and rituximab work for front-line treatment of patients with post-transplant lymphoproliferative disorder. Post-transplant lymphoproliferative disorder (PTLD) is the name for types of lymphoma that sometimes develop in people who have had a transplant. It can affect people who are taking medicines to suppress their immune system. Tafasitamab injection is in a class of medications called monoclonal antibodies. It works by helping the body to slow or stop the growth of cancer cells. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving the combination of tafasitamab and rituximab may work better in treating patients with post-transplant lymphoproliferative disorder.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- PROCEDURE Biopsy
- PROCEDURE Positron Emission Tomography
- BIOLOGICAL Rituximab
Study Locations (3)
New Jersey
- Rutgers Cancer Institute of New Jersey - New Brunswick
North Carolina
- University of North Carolina-Hillsborough Campus - Hillsborough
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2023-03-23 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05786040
The ClinicalTrials.gov registry entry for NCT05786040 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Timothy Voorhees, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Polymorphic Post-Transplant Lymphoproliferative Disorder appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT05786040 reports 3 study locations spanning 3 distinct geographic areas - top geographies include New Jersey, North Carolina, Ohio.
Frequently Asked Questions
What is clinical trial NCT05786040 about?
NCT05786040 is a clinical study titled "Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder". This phase II trial tests how well tafasitamab and rituximab work for front-line treatment of patients with post-transplant lymphoproliferative disorder. Post-transplant lymphoproliferative disorder (PTLD) is the name for types of lymphoma that sometimes develop in people who have had a transplant. ...
What is the current status of trial NCT05786040?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2023-03-23. Estimated completion is 2027-12-31.
What conditions does trial NCT05786040 study?
This clinical trial studies the following conditions: Polymorphic Post-Transplant Lymphoproliferative Disorder, Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder.
What interventions are being tested in trial NCT05786040?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Biopsy (PROCEDURE), Positron Emission Tomography (PROCEDURE), Rituximab (BIOLOGICAL).
Who is sponsoring clinical trial NCT05786040?
This trial is sponsored by Timothy Voorhees, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05786040 being conducted?
This trial has 3 study locations across New Jersey, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Polymorphic Post-Transplant Lymphoproliferative Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Polymorphic Post-Transplant Lymphoproliferative Disorder
All registered trials for this condition
Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder
All registered trials for this condition
New Jersey
All trials with a study site in New Jersey
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.